Influenza virus type A (H1N1)

Overview

No overview information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)	2023/04/18	NCT05818124	Phase 1	Completed	Merck Sharp & Dohme LLC

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Immu-n Waker	Newton Laboratories, Inc.	55714-2596	ORAL	30 [hp_X] in 1 mL	5/21/2025
Immu-n Waker	Newton Laboratories, Inc.	55714-4862	ORAL	30 [hp_X] in 1 mL	5/21/2025
I-Waker	Newton Laboratories, Inc.	55714-4838	ORAL	30 [hp_X] in 1 mL	5/21/2025
Airway Ease	Newton Laboratories, Inc.	55714-1736	ORAL	30 [hp_X] in 1 g	5/7/2025
Airway Ease	Newton Laboratories, Inc.	55714-1536	ORAL	30 [hp_X] in 1 mL	5/7/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
FLUARIX TETRA SUSPENSION FOR INJECTION	GlaxoSmithKline Biologicals, Branch of SmithKline Beecham Pharma GmbH & Co. KG, GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals (Filling)	SIN14760P	INJECTION, SUSPENSION	15mcg HA/0.5ml	3/23/2015
SKYCELLFLU QUADRIVALENT PREFILLED SYRINGE 0.5ML	SK bioscience Co., Ltd. (L House)	SIN15781P	INJECTION	15mcg/0.5ml	8/16/2019
INFLUVAC TETRA, SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE 0.5 ML	Abbott Biologicals B.V., Abbott Biologicals B.V. (Weesp)	SIN15591P	INJECTION, SUSPENSION	15 micrograms HA/0.5ml	12/4/2018
VAXIGRIPTETRA SUSPENSION FOR INJECTION IN PREFILLED SYRINGE	SANOFI WINTHROP INDUSTRIE - LE TRAIT (Primary and secondary packager), SANOFI PASTEUR – VAL DE REUIL (VDR)	SIN15477P	INJECTION, SUSPENSION	15 mcg/0.5 ml	5/4/2018
INFLUVAC, suspension for injection 0.5ml	Abbott Biologicals B.V.	SIN13177P	INJECTION, SUSPENSION	15mcg HA/0.5 ml	1/17/2006

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
FLUMIST	astrazeneca canada inc	02352621	Spray - Nasal	32000000 FFU / 0.2 ML	N/A
FLUMIST QUADRIVALENT	astrazeneca canada inc	02426544	Spray - Nasal	32000000 FFU / 0.2 ML	10/10/2014

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

FDA Authorizes First Over-the-Counter Combination Flu and COVID-19 Test

9 months ago

• The FDA has granted marketing authorization to the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, the first over-the-counter combination test for flu and COVID-19. • This test is authorized for self-use by individuals 14 years and older with respiratory symptoms and for children aged 2-13 when administered by an adult. • The Healgen test uses a nasal swab to detect SARS-CoV-2, influenza A, and influenza B, providing results in approximately 15 minutes. • Clinical data showed the test accurately identified 92% of positive SARS-CoV-2 samples, 92.5% of positive flu A samples, and 90.5% of positive flu B samples.

Vaxxas Initiates Phase I Trial of H7N9 Avian Influenza Vaccine Delivered via HD-MAP

a year ago

• Vaxxas has begun a Phase I clinical trial for its H7N9 avian influenza A vaccine, utilizing the high-density microarray patch (HD-MAP) for intradermal delivery. • The trial will assess the safety and immunogenicity of the H7N9 vaccine delivered via HD-MAP compared to traditional needle and syringe administration in 258 healthy adults. • Vaxxas' HD-MAP offers potential advantages, including thermostability and ease of use, which could facilitate rapid and widespread vaccine deployment. • Initial results from the Phase I trial, conducted across multiple Australian sites, are expected in 2025 and will be shared with BARDA and published.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access